74071-59-3

Basic information

• Product Name: (N^α-Bzl)(N^α-Me)Arg(Tos)
• Synonyms: (N^α-Bzl)(N^α-Me)Arg(Tos)
• CAS NO: 74071-59-3
• Molecular Weight: 432.544
• Mol File: 74071-59-3.mol

Chemical Properties

• CAS DataBase Reference: (N^α-Bzl)(N^α-Me)Arg(Tos)(CAS DataBase Reference)
• NIST Chemistry Reference: (N^α-Bzl)(N^α-Me)Arg(Tos)(74071-59-3)
• EPA Substance Registry System: (N^α-Bzl)(N^α-Me)Arg(Tos)(74071-59-3)

Safety Data

• Hazardous Substances Data: 74071-59-3(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 4353-32-6 N^G-tosylargine 
• 50-00-0 formaldehyd 
• 74071-58-2 (N^α-Bzl)Arg(Tos) 

Downstream Products

• 136620-33-2 Mba(SEt)-(N^α-Me)Arg(Tos)-Gly-Asp(O-cHex)-Man(4-MeBzl) 
• 136642-76-7 Boc(N^α-Me)Arg(Tos)-Gly-Asp(O-cHex)-Man(4-MeBzl) 
• 136620-31-0 (N^α-Me)Arg(Tos)-Gly-Asp(O-cHex)-Man(4-MeBzl) 
• 108695-16-5 Boc-N-Me-Arg(Tos)-OH 
• 74071-60-6 (N^α-Me)Arg(Tos) 

Relevant articles and documents

Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation

Structure-activity studies have been pursued on cyclo-S,S-[Ac-Cys-(N(α)- Me)Arg-Gly-Asp-Pen]-NH2, 2 (SK and F 106760), a potent inhibitor of platelet aggregation, in an effort to improve potency and affinity for the GPIIb/IIIa receptor. Modific

Development of a Small RGD Peptide Fibrinogen Receptor Antagonist with Potent Antiaggregatory Activity in Vitro

The development of potent antithrombotic agents from the fibrinogen platelet receptor binding sequences Fg-α 572-575 -Arg-Gly-Asp-Ser- and Fg-γ 400-411 -HHLGGAKQAGDV, believed to be a cryptic RGD-type sequence, is described.The tetrapeptide Ac-RGDS-NH2 it